Literature DB >> 30359694

Up-regulation of protective neuronal MicroRNAs by FTY720 and novel FTY720-derivatives.

Javier Vargas-Medrano1, Barbara Yang1, Nathan T Garza1, Ismael Segura-Ulate1, Ruth G Perez2.   

Abstract

In searching for Parkinson's disease (PD) pharmacotherapies we began studying FTY720, a food and drug administration (FDA) approved drug. We also created derivatives, FTY720-C2 and FTY720-Mitoxy, and began assessing them. Here we treated dopaminergic MN9D cells with FTY720s then measured microRNA (miRNA) levels by PCR arrays. We discovered that all three FTY720s increased miR376b-3p, while FTY720-C2 also increased miR-128-3p, miR-146b-5p, miR-7a-5p, and miR-9-5p, and FTY720-Mitoxy also increased miR-30d-5p. Investigations revealed that some miRNAs downregulate alpha-synuclein, while others reduce apoptosis, suggesting that FTY720s may act to reduce synucleinopathy and dopaminergic neuron loss in PD and related disorders.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dopaminergic MN9D cells; Neuroprotection; miRNA upregulation

Mesh:

Substances:

Year:  2018        PMID: 30359694     DOI: 10.1016/j.neulet.2018.10.040

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  FTY720-Mitoxy reduces toxicity associated with MSA-like α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures.

Authors:  Javier Vargas-Medrano; Ismael Segura-Ulate; Barbara Yang; Ramesh Chinnasamy; Jeffrey B Arterburn; Ruth G Perez
Journal:  Neuropharmacology       Date:  2019-07-07       Impact factor: 5.250

Review 2.  Parkinson's disease and microRNAs - Lessons from model organisms and human studies.

Authors:  Brian Evans; Howard A Furlong; Alexandre de Lencastre
Journal:  Exp Gerontol       Date:  2021-10-08       Impact factor: 4.032

3.  microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate.

Authors:  María I Dominguez-Mozo; Ignacio Casanova; Laura De Torres; Yolanda Aladro-Benito; Silvia Perez-Perez; Angel Garcia-Martínez; Patricia Gomez; Sara Abellan; Esther De Antonio; Carlos Lopez-De-Silanes; Roberto Alvarez-Lafuente
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

4.  FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models.

Authors:  Guadalupe Vidal-Martinez; Ismael Segura-Ulate; Barbara Yang; Valeria Diaz-Pacheco; Jose A Barragan; Jocelyn De-Leon Esquivel; Stephanie A Chaparro; Javier Vargas-Medrano; Ruth G Perez
Journal:  Exp Neurol       Date:  2019-11-18       Impact factor: 5.330

Review 5.  Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.

Authors:  Lisa Mészáros; Alana Hoffmann; Jeanette Wihan; Jürgen Winkler
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

Review 6.  Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis.

Authors:  Somsankar Dasgupta; Swapan K Ray
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

7.  Long Non-coding RNA Maternally Expressed 3 Increases the Expression of Neuron-Specific Genes by Targeting miR-128-3p in All-Trans Retinoic Acid-Induced Neurogenic Differentiation From Amniotic Epithelial Cells.

Authors:  Yuhua Gao; Ranxi Zhang; Guanghe Wei; Shanshan Dai; Xue Zhang; Wancai Yang; Xiangchen Li; Chunyu Bai
Journal:  Front Cell Dev Biol       Date:  2019-12-23

Review 8.  Recent Insights into the Interplay of Alpha-Synuclein and Sphingolipid Signaling in Parkinson's Disease.

Authors:  Joanna A Motyl; Joanna B Strosznajder; Agnieszka Wencel; Robert P Strosznajder
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

9.  A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models.

Authors:  Guadalupe Vidal-Martinez; Brandon Chin; Cynthia Camarillo; Gloria V Herrera; Barbara Yang; Irene Sarosiek; Ruth G Perez
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

10.  Down-regulation of Xist and Mir-7a-5p improves LPS-induced myocardial injury.

Authors:  Dongshi Liang; Yimei Jin; Miaomiao Lin; Xiaojiao Xia; Xiaoli Chen; Airong Huang
Journal:  Int J Med Sci       Date:  2020-09-16       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.